![Molecular profiles of genomically High Risk ER+ HER2- breast cancer tumors classified as functionally Basal or Luminal B by the BluePrint - Agendia Inc. Molecular profiles of genomically High Risk ER+ HER2- breast cancer tumors classified as functionally Basal or Luminal B by the BluePrint - Agendia Inc.](https://agendia.com/wp-content/uploads/2021/07/ASCO-2021-ERBasal_LuminalB_final-poster-3-1024x512.png)
Molecular profiles of genomically High Risk ER+ HER2- breast cancer tumors classified as functionally Basal or Luminal B by the BluePrint - Agendia Inc.
![Table 2 from Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. | Semantic Scholar Table 2 from Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/5582615f848e686710455b6e112e876e1ab5fb5a/3-Table2-1.png)
Table 2 from Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. | Semantic Scholar
![PLC-gamma-1 phosphorylation status is prognostic of metastatic risk in patients with early-stage Luminal-A and -B breast cancer subtypes | BMC Cancer | Full Text PLC-gamma-1 phosphorylation status is prognostic of metastatic risk in patients with early-stage Luminal-A and -B breast cancer subtypes | BMC Cancer | Full Text](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs12885-019-5949-x/MediaObjects/12885_2019_5949_Fig4_HTML.png)
PLC-gamma-1 phosphorylation status is prognostic of metastatic risk in patients with early-stage Luminal-A and -B breast cancer subtypes | BMC Cancer | Full Text
![Heterocellular gene signatures reveal luminal-A breast cancer heterogeneity and differential therapeutic responses | npj Breast Cancer Heterocellular gene signatures reveal luminal-A breast cancer heterogeneity and differential therapeutic responses | npj Breast Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41523-019-0116-8/MediaObjects/41523_2019_116_Fig1_HTML.png)
Heterocellular gene signatures reveal luminal-A breast cancer heterogeneity and differential therapeutic responses | npj Breast Cancer
![Identifying the Best Ki67 Cut-Off for Determining Luminal Breast Cancer Subtypes Using Immunohistochemical Analysis and PAM50 Genomic Classification - European Medical Journal Identifying the Best Ki67 Cut-Off for Determining Luminal Breast Cancer Subtypes Using Immunohistochemical Analysis and PAM50 Genomic Classification - European Medical Journal](https://www.emjreviews.com/wp-content/uploads/2020/11/Figure-1-Concordance-between-immunohistochemistry-and-PAM50-using-two-different-cut-off-values.jpg)
Identifying the Best Ki67 Cut-Off for Determining Luminal Breast Cancer Subtypes Using Immunohistochemical Analysis and PAM50 Genomic Classification - European Medical Journal
![Les 12 questions les plus souvent posées sur le cancer du #sein en consultation - HC Ceuta, Centro Médico de Especialidades | Centro Médico de Especialidades Les 12 questions les plus souvent posées sur le cancer du #sein en consultation - HC Ceuta, Centro Médico de Especialidades | Centro Médico de Especialidades](https://hc-ceuta.com/wp-content/uploads/2021/11/Supervivencia-grafico.png)
Les 12 questions les plus souvent posées sur le cancer du #sein en consultation - HC Ceuta, Centro Médico de Especialidades | Centro Médico de Especialidades
![Receptor-based Surrogate Subtypes and Discrepancies with Breast Cancer Intrinsic Subtypes: Implications for Image Biomarker Development | Radiology Receptor-based Surrogate Subtypes and Discrepancies with Breast Cancer Intrinsic Subtypes: Implications for Image Biomarker Development | Radiology](https://pubs.rsna.org/cms/10.1148/radiol.2018171118/asset/images/medium/radiol.2018171118.tbl1.gif)
Receptor-based Surrogate Subtypes and Discrepancies with Breast Cancer Intrinsic Subtypes: Implications for Image Biomarker Development | Radiology
![PDF] Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information | Semantic Scholar PDF] Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/a33aa443a365c6282bd5449f8899f125cb99c7a9/3-Table3-1.png)
PDF] Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information | Semantic Scholar
![Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype | BMC Research Notes | Full Text Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype | BMC Research Notes | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2F1756-0500-5-376/MediaObjects/13104_2011_Article_1552_Fig1_HTML.jpg)
Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype | BMC Research Notes | Full Text
![Biomedicines | Free Full-Text | Breast Cancer Subtype-Specific miRNAs: Networks, Impacts, and the Potential for Intervention Biomedicines | Free Full-Text | Breast Cancer Subtype-Specific miRNAs: Networks, Impacts, and the Potential for Intervention](https://www.mdpi.com/biomedicines/biomedicines-10-00651/article_deploy/html/images/biomedicines-10-00651-g001.png)
Biomedicines | Free Full-Text | Breast Cancer Subtype-Specific miRNAs: Networks, Impacts, and the Potential for Intervention
![Heterocellular gene signatures reveal luminal-A breast cancer heterogeneity and differential therapeutic responses | npj Breast Cancer Heterocellular gene signatures reveal luminal-A breast cancer heterogeneity and differential therapeutic responses | npj Breast Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41523-019-0116-8/MediaObjects/41523_2019_116_Fig6_HTML.png)
Heterocellular gene signatures reveal luminal-A breast cancer heterogeneity and differential therapeutic responses | npj Breast Cancer
![Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer - ScienceDirect Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0305737218300616-gr4.jpg)